Man Group plc bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,327 shares of the company’s stock, valued at approximately $752,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Harvest Fund Management Co. Ltd purchased a new stake in TransMedics Group during the 3rd quarter worth about $29,000. Allworth Financial LP raised its position in shares of TransMedics Group by 74.3% during the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Parallel Advisors LLC lifted its stake in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the last quarter. Ascentis Independent Advisors purchased a new stake in TransMedics Group during the first quarter worth approximately $30,000. Finally, North Star Investment Management Corp. acquired a new position in TransMedics Group in the first quarter valued at approximately $30,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at TransMedics Group
In other news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Research Report on TMDX
TransMedics Group Trading Up 3.2%
Shares of TMDX stock opened at $86.98 on Friday. The company has a market capitalization of $3.01 billion, a P/E ratio of 22.36 and a beta of 1.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The business’s 50 day moving average is $79.71 and its two-hundred day moving average is $92.23. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company had revenue of $189.95 million for the quarter, compared to analysts’ expectations of $184.00 million. During the same quarter last year, the company earned $0.92 EPS. TransMedics Group’s revenue for the quarter was up 20.7% compared to the same quarter last year. Equities analysts forecast that TransMedics Group, Inc. will post 1.46 EPS for the current year.
About TransMedics Group
TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.
TransMedics currently markets two commercially available OCS platforms.
Featured Articles
- Five stocks we like better than TransMedics Group
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
